We are live on
!
Find out more
State Street SPDR S&P Biotech ETF
713 hedge funds and large institutions have $7.23B invested in State Street SPDR S&P Biotech ETF in 2023 Q1 according to their latest regulatory filings, with 76 funds opening new positions, 229 increasing their positions, 237 reducing their positions, and 95 closing their positions.
New
Increased
Maintained
Reduced
Closed
15.89% more ownership
Funds ownership: 94.86% → 110.75% (+16%)
3% less repeat investments, than reductions
Existing positions increased: 229 | Existing positions reduced: 237
4% less funds holding
Funds holding: 746 → 713 (-33)
12% less capital invested
Capital invested by funds: $8.21B → $7.23B (-$977M)
20% less first-time investments, than exits
New positions opened: 76 | Existing positions closed: 95
26% less funds holding in top 10
Funds holding in top 10: 31 → 23 (-8)
32% less call options, than puts
Call options by funds: $1.15B | Put options by funds: $1.7B
Holders
713
Holders Change
-33
Holders Change %
-4.42%
% of All Funds
11.36%
Holding in Top 10
23
Holding in Top 10 Change
-8
Holding in Top 10 Change %
-25.81%
% of All Funds
0.37%
New
76
Increased
229
Reduced
237
Closed
95
Calls
$1.15B
Puts
$1.7B
Net Calls
-$543M
Net Calls Change
-$894M
Top Buyers
| 1 |
JP Morgan Chase
New York
|
+$401M |
| 2 |
Barclays
London,
United Kingdom
|
+$284M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$115M |
| 4 |
Jane Street
New York
|
+$96.4M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$85.4M |
